Core Viewpoint - Shenzhen Nengfeng Smart Technology Co., Ltd. has been established, focusing on emerging energy technology research and development, manufacturing of photovoltaic equipment and components, motor manufacturing, wind power technology services, and energy management services [1] Company Summary - The legal representative of Shenzhen Nengfeng Smart Technology Co., Ltd. is Shi Lei [1] - The company is wholly owned by Shenzhen Yichu Smart Energy Group Co., Ltd., which is held by Ganfeng Lithium [1]

Group 1 - The Hong Kong pharmaceutical market saw a significant rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 3% and achieving a trading volume exceeding 900 million yuan, reflecting strong capital inflow [1] - The ETF's latest scale has surpassed 21.4 billion yuan, leading its peers in the same category [1] - The "20CM Innovation Drug New Species" ETF from Huatai-PineBridge (589120) surged by 4%, with strong capital inflow for two consecutive days [1] Group 2 - Rongchang Biopharmaceutical announced the approval of its antibody-drug conjugate (ADC) Vidi Xituzumab (brand name: Aidiqi®) for a new indication, making it the first domestic ADC therapy approved for treating adult breast cancer patients with low HER2 expression and liver metastasis [3] - Gilead Sciences agreed to acquire Ouro Medicines, which holds approximately 15% equity in Ouro, marking a strategic move in the biopharmaceutical sector [3] Group 3 - WuXi AppTec reported a record high in 2025, achieving revenue of 45.456 billion yuan, a year-on-year increase of 15.8%, and a net profit of 19.195 billion yuan, up 105.2% year-on-year [4] Group 4 - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw most of its underlying index stocks perform positively, with notable gains from companies like Connaissance-B, which rose over 4%, and others like Innovent Biologics and Rongchang Biopharmaceutical, which increased by over 2% [5] Group 5 - The AACR 2026 conference will take place in San Diego, featuring numerous innovative pharmaceutical companies discussing breakthroughs from basic research to clinical translation [6] - Key presentations will include Merck's disclosure of clinical data for MK-2010 and updates from various companies on their clinical trials and research advancements [6][7][8][9] Group 6 - The innovation drug sector is experiencing a surge in funding, with approximately 700 billion yuan raised for research and development from January 1, 2024, to March 21, 2026, across Hong Kong and A-share markets [10] - The BD income and post-listing fundraising are providing substantial financial support for innovative drug companies [10][15] Group 7 - Despite short-term volatility in the innovation drug sector, the long-term growth potential remains intact, with a focus on overseas clinical deployment and product progress becoming critical for future success [16][17] - Leading innovative drug companies are entering a positive cycle of product commercialization, which is expected to exceed market expectations [18]

Core Viewpoint - The China Development Forum 2026 focuses on "China's 14th Five-Year Plan: High-Quality Development and Co-Creating New Opportunities" and highlights the role of blockchain technology in addressing challenges in international cross-border trade [1][5]. Group 1: Blockchain Technology in Trade - The "航贸数链" project utilizes blockchain to tackle three major pain points in international trade: information asymmetry, high trust costs, and complex supply chain layers [3][7]. - Data transparency is emphasized as a solution to trust issues, with documents, contracts, and logistics data being stored on the blockchain, ensuring immutability and traceability [8]. - Process penetration is highlighted to enhance efficiency, with the time for verifying offshore trade documents reduced from at least 2 days to 30 minutes, and oil and gas transaction document verification time cut from 6 hours to 10 minutes [8]. Group 2: Collaboration and Market Impact - The project addresses collaboration issues by integrating various stakeholders in the supply chain, leading to smoother operations and reducing common logistical problems [4][8]. - Approximately 300,000 enterprises have joined the platform, with transaction volumes reaching 1 trillion RMB, indicating strong market acceptance [4][8]. - The potential applications of blockchain technology extend beyond cross-border trade to include multimodal transport, large-scale supply chain financing, letters of credit in trade, and innovations in digital currency [9]. Group 3: Insights and Future Directions - The importance of high-level openness for innovation is underscored, suggesting that without such an environment, similar innovations would not emerge [9]. - The integration of cutting-edge technologies is seen as having limitless potential to transform financial operations [9]. - Emphasizing the need for financial services to remain rooted in the real economy, it is noted that without market participants, financial innovations lack rich scenarios for application [9].

3月23日晚，碧桂园发布盈喜，预计2025年度利润介乎10亿至22亿，上年度亏损351.45亿元。根据目前 可获得的资料，本年度转亏为盈主要由于集团完成债务重组录得的非现金收益所致。撇除前述债务重组 收益的影响后，集团录得亏损主要是由于受行业影响，集团开发业务毛利水平承压，且进一步对若干资 产及物业项目计提减值准备等因素所致。 碧桂园（02007）盘中涨超6%，截至发稿，股价上涨5%，现报0.315港元，成交额3568.99万港元。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 3月23日晚，碧桂园发布盈喜，预计2025年度利润介乎10亿至22亿，上年度亏损351.45亿元。根据目前 可获得的资料，本年度转亏为盈主要由于集团完成债务重组录得的非现金收益所致。撇除前述债务重组 收益的影响后，集团录得亏损主要是由于受行业影响，集团开发业务毛利水平承压，且进一步对若干资 产及物业项目计提减值准备等因素所致。 责任编辑：卢昱君 责任编辑：卢昱君 碧桂园（02007）盘中涨超6%，截至发稿，股价上涨5%，现报0.315港元，成交额35 ...

Group 1 - The central enterprise dividend ETF, Fu Guo (159332), opened at 1.234 yuan with an increase of 0.98% on March 24 [1][2] - Major holdings of the ETF include China Merchants Industry Holdings, which rose by 0.72%, and China Shenhua Energy, which fell by 1.76% [1] - The ETF's performance benchmark is the China Central Enterprises Dividend Index return rate, managed by Fu Guo Fund Management Co., Ltd., with a return of 26.33% since its establishment on July 16, 2024, and a monthly return of 2.08% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [3]

Group 1 - The Hongli State-Owned Enterprise ETF Galaxy (530880) opened at 1.062 yuan, with an increase of 0.66% on March 24 [1][2] - Major holdings in the ETF include China Merchants Industry Holdings, which rose by 0.72%, while Shanxi Coal International, Lu'an Environmental Energy, Pingmei Shenma Energy, Hengyuan Coal Power, Shaanxi Coal and Chemical Industry, Yanzhou Coal Mining, and China Shenhua Energy experienced declines ranging from 1.14% to 2.50% [1] - The ETF's performance benchmark is the Shanghai Stock Exchange State-Owned Enterprises Dividend Index, managed by Galaxy Fund Management Co., Ltd., with a return of 9.24% since its establishment on October 30, 2024, and a return of 2.91% over the past month [2] Group 2 - A MACD golden cross signal has formed, indicating positive momentum for certain stocks [3]

Group 1 - The Shanghai 50 ETF Dongcai (530050) opened with a gain of 0.63%, priced at 1.116 yuan [1][2] - Major holdings in the Shanghai 50 ETF include Kweichow Moutai, which rose by 0.56%, Ping An of China up by 0.92%, Zijin Mining increasing by 2.19%, and others like China Merchants Bank and Industrial Bank showing modest gains [1][2] - The performance benchmark for the Shanghai 50 ETF is the return rate of the Shanghai 50 Index, managed by Dongcai Fund Management Co., with a return of 10.52% since its establishment on November 18, 2024, and a recent one-month return of -7.98% [1][2]

Group 1 - The Shanghai Stock Exchange 50 ETF Tianhong (530000) opened with a gain of 0.69%, priced at 1.322 yuan [1][2] - Major holdings in the ETF include Kweichow Moutai, which rose by 0.56%, Ping An Insurance up by 0.92%, Zijin Mining up by 2.19%, and others such as China Merchants Bank and Industrial Bank showing slight increases [1][2] - The performance benchmark for the ETF is the Shanghai 50 Index return, managed by Tianhong Fund Management Co., with a return of 29.97% since its establishment on September 4, 2024, and a recent one-month return of -7.95% [1][2]

Group 1 - The core point of the news is the performance of the Huazhang 50 ETF (510190), which opened at 4.126 yuan with a gain of 0.93% on March 24 [1][2] - Major stocks held by the Huazhang 50 ETF include Kweichow Moutai, which rose by 0.56%, Ping An of China by 0.92%, Zijin Mining by 2.19%, and others showing positive gains [1] - The Huazhang 50 ETF has a benchmark performance index of the SSE 50 Index, managed by Huazhang Fund Management Co., with a return of 56.51% since its establishment on November 18, 2010, and a recent one-month return of -7.87% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for the stocks mentioned [3]

Group 1 - The core point of the news is the performance of the Science and Technology Innovation Pharmaceutical ETF (工银, 588860), which opened with a gain of 0.48% at 0.626 yuan on March 24 [1][2] - The ETF's major holdings showed positive movements, with notable increases including Zai Lab (泽璟制药) up 2.81%, BeiGene (百济神州) up 1.90%, and Honor Bio (荣昌生物) up 2.70% [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index, managed by ICBC Credit Suisse Asset Management Company, with a return of 24.70% since its inception on August 8, 2024, and a recent one-month return of -10.90% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for the stocks mentioned [3]